Sunshine Biopharma launches generic Gabapentin for neuropathic pain in Canada
Source: SeekingAlpha
2025-06-11 08:45:08 ET
More on Sunshine Biopharma
- Seeking Alpha’s Quant Rating on Sunshine Biopharma
- Historical earnings data for Sunshine Biopharma
- Financial information for Sunshine Biopharma
Read the full article on Seeking Alpha
For further details see:
Sunshine Biopharma launches generic Gabapentin for neuropathic pain in Canada
Sunshine Biopharma Inc.
NASDAQ: SBFM
SBFM Trading
385.58% G/L:
$1.70 Last:
252,494,325 Volume:
$1.84 Open:
SBFM Latest News
April 06, 2026 08:30:00 am
Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior YearOctober 28, 2025 02:10:00 pm
Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)October 28, 2025 07:45:00 am
Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related NauseaOctober 20, 2025 07:45:00 am
Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy DoxycyclineSBFM Stock Data
$5,421,575
4,505,830
0.12%
10
N/A
Pharmaceuticals
Healthcare
CA
Fort Lauderdale
